09:28 AM EDT, 10/03/2024 (MT Newswires) -- Eli Lilly's ( LLY ) weight-loss drug Mounjaro will be offered to patients most in need across England through a phased government rollout, the National Institute for Health and Care Excellence, or NICE, said Thursday.

Britain's National Health Service is proposing a phased rollout of Mounjaro, also known as Zepbound in the US, that will prioritize certain patients with obesity in "a variety of new services that will be tested before an expansion of the drug's availability," NICE said.

In draft guidance issued in June, an independent NICE panel recommended the weekly injection, which costs 122 British pounds ($160) a month at its maximum 15 milligram dose list price, for people with obesity, NICE said.

Price: 892.16, Change: +1.09, Percent Change: +0.12